Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF) announced that CEO Jeff Goater and CMO Robert Ross will participate in the H.C. Wainwright Global Healthcare Conference on September 14-15, 2020. They will discuss the company's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), along with their emerging pre-clinical pipeline, including SRF813 (targeting CD112R, aka PVRIG). Surface is focused on developing next-generation immunotherapies that target the tumor microenvironment, aiming to achieve sustained anti-tumor responses.

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) --  Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming H.C. Wainwright Global Healthcare Conference held on September 14/15, 2020, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG).

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), a clinical-stage collaboration with Novartis targeting CD73 (NZV930), and two preclinical programs, each focused primarily on activating natural killer cells (via targeting CD112R, also known as PVRIG (SRF813)) or depleting regulatory T cells (via targeting CCR8 (SRF114)). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:
Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Tom Donovan
tom@tenbridgecommunications.com
857-559-3397

FAQ

What is the focus of Surface Oncology's lead programs SRF617 and SRF388?

Surface Oncology's lead programs, SRF617 and SRF388, focus on targeting CD39 and IL-27, respectively.

When will Surface Oncology participate in the H.C. Wainwright Global Healthcare Conference?

Surface Oncology will participate in the H.C. Wainwright Global Healthcare Conference on September 14-15, 2020.

What is the significance of SRF813 in Surface Oncology's pipeline?

SRF813, targeting CD112R (PVRIG), is part of Surface Oncology's emerging pre-clinical pipeline aimed at enhancing immunotherapy.

What type of therapies is Surface Oncology developing?

Surface Oncology is developing next-generation immunotherapies focused on the tumor microenvironment.

Where can I find more information about Surface Oncology?

Additional information about Surface Oncology can be found on their official website at www.surfaceoncology.com.